CODX - Co-DiagnosticsAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $16.93 | Open | $16.42 |
| Volume | 2.41M | Market Cap | 13.95M |
| Yield | Last Dividend |
| Can CoDiagnostics, Inc. (CODX) Run Highe... | 05/21/20 |
| CoDiagnostics, Inc. (CODX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revi... | |
| CoDiagnostics, Inc. (CODX) Moves to Stro... | 05/21/20 |
| CoDiagnostics, Inc. (CODX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This... | |
| Is CoDiagnostics (CODX) Outperforming Ot... | 05/21/20 |
| Is (CODX) Outperforming Other Medical Stocks This Year? | |
| Top Analyst Upgrades and Downgrades: Abb... | 05/20/20 |
| No summary available. | |
| Top Analyst Upgrades and Downgrades: App... | 05/18/20 |
| No summary available. | |
| The Daily Biotech Pulse: Co-Diagnostics ... | 05/15/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) Allo... | |
| CoDiagnostics, Inc. (CODX) Reports Q1 Lo... | 05/14/20 |
| CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -25.00% and 40.82%, respectively, for the quarter ended March 2020. Do the numb... | |
| Why Co-Diagnostics Stock Is Jumping Toda... | 05/14/20 |
| Another COVID-19 test maker's pain appears to be behind Co-Diagnostics stock's gain. | |
| CoDiagnostics Inc (CODX) Gains As Market... | 05/12/20 |
| CoDiagnostics Inc (CODX) closed at $17.11 in the latest trading session, marking a +0.38% move from the prior day. | |
| Thinking about buying stock in Chembio D... | 04/20/20 |
| NEW YORK, April 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEMI, CODX, DD, F, and KHC. To see how InvestorsObser... | |
| Co-Diagnostics, Inc. Announces Expansion... | 04/20/20 |
| SALT LAKE CITY, April 20, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the Company), a molecular diagnostics company with a unique, paten... | |
| Thinking about buying stock in Bed Bath ... | 04/16/20 |
| NEW YORK, April 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBBY, CGEN, CODX, GE, and TRIP. To see how InvestorsO... | |
| Co-Diagnostics, Inc. COVID-19 Test Techn... | 04/16/20 |
| Co-Diagnostics, Inc. (Nasdaq: CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of molecular d... | |
| With FDA Approval in Place, Is Co-Diagno... | 04/14/20 |
| No summary available. | |
| What Is FDA Emergency Use Authorization? | 04/11/20 |
| As companies announce the marketing or development of diagnostic tests for the new coronavirus, they invariably reference an Emergency Use Authorizati... | |
| Co-Diagnostics COVID-19 Test Gets FDA Em... | 04/06/20 |
| Co-Diagnostics Inc (NASDAQ: CODX ) shares are getting boost on Monday. The positive reaction is in the wake of an announcement from the company that i... | |
| Co-Diagnostics, Inc Receives FDA Emergen... | 04/06/20 |
| Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic test... | |
| Co-Diagnostics Stock Is Not a Penny Stoc... | 03/31/20 |
| No summary available. | |
| Co-Diagnostics, Inc. Reports 2019 Year-E... | 03/31/20 |
| SALT LAKE CITY--(BUSINESS WIRE)---- $CODX--Co-Diagnostics, Inc. reports 2019 year-end financial results and progress updates | |
| Co-Diagnostics??? COVID-19 Test Passes C... | 03/26/20 |
| It might be churlish to suggest there are winners in times of a global pandemic, but it is an unavoidable fact that some companies have benefited from... | |
| Co-Diagnostics Stock Is a Long-term Play... | 03/26/20 |
| Due to its extreme swings, CODX stock isn???t necessarily a buy right now. However, its longer-term viability is no longer in doubt. | |
| Co-Diagnostics, Inc Completes Successful... | 03/20/20 |
| SALT LAKE CITY--(BUSINESS WIRE)---- $CODX #COVID19--Co-Diagnostics completes successful clinical evaluation required for FDA EUA; Company accelerates ... | |
| Co-Diagnostics JV CoSara First Indian Co... | 03/19/20 |
| SALT LAKE CITY--(BUSINESS WIRE)-- #COVID19--Co-Diagnostics JV CoSara is the first Indian company to receive a license to manufacture a COVID-19 PCR di... | |
| Co-Diagnostics Sees 'Aggressive Expansio... | 03/17/20 |
| Co-Diagnostics Inc (NASDAQ: CODX ) shares were rallying Tuesday following an update from the company regarding its COVID-19 test. The molecular diagno... | |
| Dow Jones Today, Stocks Bounce; Coronavi... | 03/17/20 |
| Moderna and Regeneron took early leads, as stock futures and the Dow Jones set up for an early rebound from Monday's lows. | |
| Three biotech stocks popped up today on ... | 03/17/20 |
| Biotech companies all over the world have been trying to find the treatment and vaccine for the coronavirus pandemic since January of this year. In th... | |
| Co-Diagnostics says new FDA policy to he... | 03/17/20 |
| Co-Diagnostics Inc said on Tuesday the U.S. Food and Drug Administrations new policy to expand availability of COVID-19 tests will allow the medical t... | |
| FDA Policy Change to Allow Rapid Domesti... | 03/17/20 |
| SALT LAKE CITY--(BUSINESS WIRE)---- $CODX #COVID19--FDA policy change to allow rapid domestic expansion of Co-Diagnostics COVID-19 test, without first... | |
| Buy rating | 05/20/20 |
| Maxim Group upgrades from Hold to Buy rating and announces Price Target of $30.00 | |
| Buy rating | 05/18/20 |
| and raises Price Target from $20.00 to $35.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Short & Long | Short & Long | 88.00 % | Subscribe |
| Tech Trades | Tech Trades | 85.00 % | Follow |
| Big Data Zhou | Zhou Academy | 81.00 % | Subscribe |
| Option short-term trading [Unusual] | Debashis K | 66.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
